Omar Kayaleh

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart et al. · The Lancet Oncology · 2015 · 248 citations

Investigational Aurora, Medicine, Pharmacology +7

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel et al. · British Journal of Cancer · 2014 · 121 citations · Full text

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Andrew H. Ko, Hagop Youssoufian, Jayne Gurtler et al. · Investigational New Drugs · 2011 · 60 citations

First-line Therapy, Pancreatic Cancer, Phase Ii +8

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene–environment interaction

Mitchell Cheung, Yuwaraj Kadariya, Jacqueline Talarchek et al. · Cancer Letters · 2015 · 48 citations · Full text

Potential Gene–environment Interaction, Cancer Epidemiology, Germline Bap1 Mutation +10

A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer

Henry Q. Xiong, Kenneth R. Hess, Omar Kayaleh et al. · Journal of Clinical Oncology · 2005 · 12 citations

Surgical Oncology, Chemoprevention Strategy, Pathology +17